Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A&nbsp;single‑center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

Yang,Hong; Wang,Rong; Zeng,Furen; Zhao,Jie; Peng,Shunli; Ma,Yueyun; Chen,Shiyu; Ding,Sijie; Zhong,Longhui; Guo,Wei; Wang,Wei

doi:10.3892/ol.2020.11948

Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single‑center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

Authors:
- Hong Yang
- Rong Wang
- Furen Zeng
- Jie Zhao
- Shunli Peng
- Yueyun Ma
- Shiyu Chen
- Sijie Ding
- Longhui Zhong
- Wei Guo
- Wei Wang
View Affiliations

Affiliations: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, P.R. China, Department of Pathology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, P.R. China
Published online on: August 5, 2020 https://doi.org/10.3892/ol.2020.11948
Article Number: 87
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is a highly heterogeneous disease at the molecular level and >90% of mortalities are due to metastasis and its associated complications. The present study determined the impact of molecular subtypes on metastatic behavior and overall survival (OS) of patients with metastatic breast cancer. The influence of molecular subtypes on the sites and number of metastases in 166 patients with metastatic breast cancer from a single center were assessed; and the influence of molecular subtypes on the sites and number of metastases and OS in 15,322 metastatic cases among 329,770 patients with primary breast cancer from the Surveillance, Epidemiology and End Results database were assessed. Analysis of both datasets revealed that different molecular subtypes exhibited differences in the prevalence of different metastatic sites and number of metastases. A larger proportion of bone metastasis was observed in the hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)+ subtype than in other subtypes, more lung metastasis was observed in the HR‑/HER2+ subtype and more liver metastasis occurred in the HR+/HER2+ and HR‑/HER2+ subtypes. Single‑site metastasis was more common for the HR+/HER2‑ subtype than in other subtypes, while 2‑3 sites of metastases were more common for the HR+/HER2+ subtype and ≥4 sites of metastases were more frequent in the HR‑/HER2+ and HR‑/HER2‑ subtypes. The mean OS of patients with primary breast cancer in the HR+/HER2‑ subtype group was the longest (78.5 months), while the HR‑/HER2‑ group had the shortest mean OS (69.1 months). The mean OS of the metastatic HR+/HER2+ group was the longest (46.0 months), while the mean OS of the metastatic HR‑/HER2‑ group was the shortest (18.5 months). In conclusion, the results of the present study suggested that different molecular subtypes of breast cancer have different metastatic behavior, as well as mean OS

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Santa-Maria CA, Nye L, Mutonga MB, Jain S and Gradishar WJ: Management of Metastatic HER2-positive breast cancer: Where are we and where do we go from here? Oncology (Williston Park). 30:148–155. 2016.PubMed/NCBI
3	Puglisi F, Rea D, Kroes MA and Pronzato P: Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. Cancer Treat Rev. 43:36–49. 2016. View Article : Google Scholar : PubMed/NCBI
4	Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G and Puglisi F: Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 32:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
5	Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, et al: Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: A nationwide cohort study. Breast Cancer Res. 13:R872011. View Article : Google Scholar : PubMed/NCBI
6	Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA and Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68:3108–3114. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI
8	Berman AT, Thukral AD, Hwang WT, Solin LJ and Vapiwala N: Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 13:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
9	Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 45:2792–2798. 2009. View Article : Google Scholar : PubMed/NCBI
10	Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A and Cardoso F: Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX. J Clin Oncol. 31:3083–3090. 2013. View Article : Google Scholar : PubMed/NCBI
11	Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R and Kaufman B: Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients. Am J Clin Oncol. 32:504–508. 2009. View Article : Google Scholar : PubMed/NCBI
12	Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P and Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 115:423–428. 2009. View Article : Google Scholar : PubMed/NCBI
13	Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C, Fasola G and Puglisi F: Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis. 30:951–956. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, et al: The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol. 112:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hammond ME, Hayes DF, Wolff AC, Mangu PB and Temin S: American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 6:195–197. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kimbung S, Loman N and Hedenfalk I: Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 35:85–95. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
19	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ; Panel members, : Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Onco. 22:1736–1747. 2011. View Article : Google Scholar
20	Ongaro E, Gerratana L, Cinausero M, Pelizzari G, Poletto E, Giangreco M, Andreetta C, Pizzolitto S, Di Loreto C, Minisini AM, et al: Comparison of primary breast cancer and paired metastases: Biomarkers discordance influence on outcome and therapy. Future Oncol. 14:849–859. 2018. View Article : Google Scholar : PubMed/NCBI
21	Killelea BK, Gallagher EJ, Feldman SM, Port E, King T, Boolbol SK, Franco R, Fei K, Le Roith D and Bickell NA: The effect of modifiable risk factors on breast cancer aggressiveness among black and white women. Am J Surg. 218:689–694. 2019. View Article : Google Scholar : PubMed/NCBI
22	Fujii K, Watanabe R, Ando T, Kousaka J, Mouri Y, Yoshida M, Imai T, Nakano S and Fukutomi T: Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions. Biomed Rep. 7:535–542. 2017.PubMed/NCBI
23	Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP and Wei S: Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 143:471–478. 2015. View Article : Google Scholar : PubMed/NCBI
24	Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, He W and Zhang S: Seeking for correlative genes and signaling pathways with bone metastasis from breast cancer by integrated analysis. Front Oncol. 9:1382019. View Article : Google Scholar : PubMed/NCBI
26	Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
27	Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, et al: Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer. Cancer Res. 79:4211–4226. 2019. View Article : Google Scholar : PubMed/NCBI
28	Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D and Hung MC: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
29	Wu W, Chen J, Ye W, Li X and Zhang J: Fatty liver decreases the risk of liver metastasis in patients with breast cancer: A two-center cohort study. Breast Cancer Res Treat. 166:289–297. 2017. View Article : Google Scholar : PubMed/NCBI
30	Park HS, Kim S, Kim K, Yoo H, Chae BJ, Bae JS, Song BJ and Jung SS: Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer. World J Surg Oncol. 10:42012. View Article : Google Scholar : PubMed/NCBI
31	Carvalho ST, Stiepcich MM, Fregnani JH, Nonogaki S, Rocha R and Soares FA: Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics (Sao Paulo). 66:607–612. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K and Connolly EP: Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springer Plus. 4:3862015. View Article : Google Scholar : PubMed/NCBI
33	Giuli MV, Giuliani E, Screpanti I, Bellavia D and Checquolo S: Notch signaling activation as a hallmark for triple-negative breast cancer subtype. J Oncol. 2019:87070532019. View Article : Google Scholar : PubMed/NCBI
34	Press DJ, Miller ME, Liederbach E, Yao K and Huo D: De novo metastasis in breast cancer: Occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 34:457–465. 2017. View Article : Google Scholar : PubMed/NCBI
35	Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, et al: Measures of outcome in metastatic breast cancer: Insights from a real-world scenario. Oncologist. 19:608–615. 2014. View Article : Google Scholar : PubMed/NCBI